Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis

作者：Richardson Timothy E; Shen Zhong Jian; Kanchwala Mohammed; Xing Chao; Filatenkov Alexander; Shang Ping; Barnett Samuel; Abedin Zahidur; Malter James S; Raisanen Jack M; Burns Dennis K; White Charles L; Hatanpaa Kimmo J^*

来源：Journal of Neuropathology and Experimental Neurology, 2017, 76(10): 874-882.

DOI：10.1093/jnen/nlx072

• ARG2
• HLA-B
• Null cell adenoma
• Pituitary adenoma
• SEMA3A
• Silent subtype III
• Transcriptome sequencing

Silent subtype III pituitary adenomas (SS-3) are clinically nonfunctional adenomas that are more aggressive in terms of invasion and risk of recurrence than their conventional null cell counterparts. We previously showed that these tumors can be distinguished by immunohistochemistry based on the identification of a markedly enlarged and fragmented Golgi apparatus. To understand the molecular correlates of differential aggressiveness, we performed whole transcriptome sequencing (RNAseq) on 4 SS-3 and 4 conventional null cell adenomas. The genes that were highly upregulated in all the SS-3 adenomas included 2 secreted proteins involved in the suppression of T-lymphocyte activity, i.e., ARG2 (multiple testing adjusted p(adj) = 1.5 x 10(-3)) and SEMA3A (p(adj) = 3.3 x 10(-3)). Highly downregulated genes in all the SS-3 adenomas included HLA-B (p(adj) = 3.3 x 10(-6)), suggesting reduced antigen presentation by the adenoma to cytotoxic T-cells. Quantitative RT-PCR of these genes performed on the adenoma samples supported the RNAseq results. We also found a relative decrease in the overall concentration of T-lymphocytes in the SS-3 tumors. These results suggest that SS-3 adenomas actively suppress the immune system and raise the possibility that they may be treatable with immune checkpoint inhibitors or nonspecific cancer immunotherapies.

• 出版日期2017-10